Amibegron

Amibegron
Clinical data

Routes of administration	Oral
ATC code	none
Legal status
Legal status	Development terminated
Identifiers
IUPAC name Ethyl ([(7S)-7-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)acetate
CAS Number	121524-09-2
PubChem (CID)	3035442
IUPHAR/BPS	568
ChemSpider	108738^Y
UNII	PDQ3ME68U3^Y
KEGG	D08851^Y
ChEMBL	CHEMBL545437^Y
Chemical and physical data
Formula	C₂₂H₂₆ClNO₄
Molar mass	403.898 g/mol
3D model (Jmol)	Interactive image
SMILES CCOC(=O)COc3ccc1CCC(Cc1c3)NCC(O)c2cc(Cl)ccc2
InChI InChI=1S/C22H26ClNO4.ClH/c1-2-27-22(26)14-28-20-9-7-15-6-8-19(11-17(15)12-20)24-13-21(25)16-4-3-5-18(23)10-16;/h3-5,7,9-10,12,19,21,24-25H,2,6,8,11,13-14H2,1H3;1H/t19-,21-;/m0./s1^Y Key:NQIZCDQCNYCVAS-RQBPZYBGSA-N^Y

Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis (now Sanofi) which acts as a selective agonist for the β₃ adrenergic receptor. It is the first orally active β₃ agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects.

On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.